GLP-1 receptor agonists like semaglutide and liraglutide appear to reduce both nicotine cravings and appetite by modulating central reward pathways in the brain. Preclinical studies and limited clinical trials suggest these diabetes medications could address the major barrier to smoking cessation: post-quit weight gain that drives many people back to cigarettes. This represents a potentially transformative approach to addiction medicine. Most smoking cessation aids focus solely on nicotine replacement or craving reduction, leaving users vulnerable to the metabolic rebound that follows nicotine withdrawal. GLP-1 agonists could theoretically break this cycle by simultaneously dampening reward-seeking behavior for both food and nicotine. However, the clinical evidence remains thin—small studies with brief follow-ups hardly constitute proof of concept. The review acknowledges this limitation while highlighting the biological plausibility. Given that post-cessation weight gain affects 80% of quitters and contributes significantly to relapse rates, any intervention addressing both targets deserves serious investigation. The confluence of the obesity and smoking epidemics makes this dual-action strategy particularly relevant, though definitive randomized trials are essential before clinical implementation.